- Home
- QBTS vs CHRS Comparison
QBTS vs CHRS Comparison
Compare QBTS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QBTS
- CHRS
- Stock Information
- Founded
- QBTS 1999
- CHRS 2010
- Country
- QBTS United States
- CHRS United States
- Employees
- QBTS N/A
- CHRS N/A
- Industry
- QBTS Retail: Computer Software & Peripheral Equipment
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QBTS Technology
- CHRS Health Care
- Exchange
- QBTS Nasdaq
- CHRS Nasdaq
- Market Cap
- QBTS 5.0B
- CHRS 84.2M
- IPO Year
- QBTS N/A
- CHRS 2014
- Fundamental
- Price
- QBTS $16.62
- CHRS $0.82
- Analyst Decision
- QBTS Strong Buy
- CHRS Buy
- Analyst Count
- QBTS 7
- CHRS 3
- Target Price
- QBTS $13.57
- CHRS $4.68
- AVG Volume (30 Days)
- QBTS 52.7M
- CHRS 1.3M
- Earning Date
- QBTS 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- QBTS N/A
- CHRS N/A
- EPS Growth
- QBTS N/A
- CHRS N/A
- EPS
- QBTS N/A
- CHRS N/A
- Revenue
- QBTS $21,363,000.00
- CHRS $272,251,000.00
- Revenue This Year
- QBTS $181.95
- CHRS N/A
- Revenue Next Year
- QBTS $55.49
- CHRS $106.56
- P/E Ratio
- QBTS N/A
- CHRS $1.87
- Revenue Growth
- QBTS 121.61
- CHRS 19.87
- 52 Week Low
- QBTS $0.75
- CHRS $0.66
- 52 Week High
- QBTS $19.77
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- QBTS 56.67
- CHRS 53.13
- Support Level
- QBTS $13.57
- CHRS $0.72
- Resistance Level
- QBTS $15.44
- CHRS $0.77
- Average True Range (ATR)
- QBTS 0.99
- CHRS 0.04
- MACD
- QBTS -0.27
- CHRS 0.01
- Stochastic Oscillator
- QBTS 70.84
- CHRS 91.62
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.